



Home	Bill Information	California Law	Publications	Other Resources	My Subscriptions	My Favorites	
------	------------------	----------------	--------------	-----------------	------------------	--------------	--

**HR-129** (2021-2022)

SHARE THIS:  

REVISED AUGUST 23, 2022

CALIFORNIA LEGISLATURE— 2021–2022 REGULAR SESSION

## HOUSE RESOLUTION

**NO. 129**

Introduced by Assembly Member Valladares

*(Coauthors: Assembly Members Aguiar-Curry, Alvarez, Arambula, Bauer-Kahan, Bennett, Berman, Bloom, Boerner Horvath, Mia Bonta, Bryan, Calderon, Carrillo, Cervantes, Chen, Choi, Cooley, Cooper, Cunningham, Megan Dahle, Daly, Flora, Fong, Mike Fong, Friedman, Gabriel, Cristina Garcia, Eduardo Garcia, Gipson, Grayson, Haney, Holden, Irwin, Jones-Sawyer, Kalra, Kiley, Lackey, Lee, Levine, Low, Maienschein, Mathis, Mayes, McCarty, McKinnor, Medina, Mullin, Muratsuchi, Nazarian, Nguyen, O'Donnell, Patterson, Petrie-Norris, Quirk, Quirk-Silva, Ramos, Rendon, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Seyarto, Smith, Stone, Ting, Villapudua, Voepel, Waldron, Ward, Akilah Weber, Wicks, Wilson, and Wood)*

August 11, 2022

Relative to Pancreatic Cancer Awareness Month.

### LEGISLATIVE COUNSEL'S DIGEST

HR 129, as introduced, Valladares.

WHEREAS, In 2022, an estimated 62,210 people will be diagnosed with pancreatic cancer and 49,830 people will die from the disease in the United States; and

WHEREAS, Pancreatic cancer is one of the deadliest cancers, is the third leading cause of cancer death in the United States, and has a five-year relative survival rate of only 11 percent; and

WHEREAS, Symptoms of pancreatic cancer usually first present themselves in its late stage. If detected at an early stage when surgical removal of a tumor is possible, the five-year survival rate is 42 percent, but only 13 percent of people are diagnosed at this stage. For 52 percent of pancreatic cancer patients where the cancer spreads to a distant part of the body, the five-year survival rate is 3 percent; and

WHEREAS, The federal government invests significantly less money in pancreatic cancer research than it does in research of any other leading deadly cancer. In 2020, the National Cancer Institute (NCI) had a budget of \$6,400,000,000. Of this, only

\$178,500,000 went towards pancreatic cancer research, which is just under 3 percent. This year, Congress provided \$6,900,000,000 for the NCI, increasing their budget by \$353,000,000 from the previous fiscal year; and WHEREAS, The Pancreatic Cancer Action Network (PanCAN) is a national organization that serves the pancreatic cancer community in its California headquarters. The organization is investing \$25,000,000 in pancreatic cancer research this year. PanCAN received 15,000,000 from Congress in this year's fiscal package; and

WHEREAS, The good health and well-being of the residents of California are enhanced as a direct result of increased awareness about pancreatic cancer and research into early detection, causes, and effective treatments; now, therefore, be it

Resolved by the Assembly of the State of California, That the Assembly hereby recognizes that pancreatic cancer statistics call for aggressive measures now to develop early detection and treatment tools before the incidence dramatically increases, in light of the fact that NCI funding is falling dangerously behind; and be it further

Resolved, That the Assembly hereby proclaims November 2022 as Pancreatic Cancer Awareness Month in California and urges all California citizens to wage hope to end pancreatic cancer; and be it further

Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.

---

REVISIONS:

Heading—Line 2.

---